Biotech Company ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) stated Thursday that Company management will attend the NobleCon15 and the Cantech Investment Conference to provide overviews of its novel drug discovery and development programs for Alzheimer's disease, Parkinson's disease and ALS (amyotrophic lateral sclerosis), and participate on discussion panels.
To find out more about these events, click here.
ProMIS made news recentlywith the appointment of Rudolph Tanzi, Ph.D, to the Company's scientific advisory board (SAB). He is also the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital.
FULL DISCLOSURE: ProMIS Neurosciences Inc. is a client of Stockhouse Publishing.